Department of Family Medicine, National Yang Ming Chiao Tung University Hospital, Yilan, Taiwan, Republic of China.
Department of Leisure Services Management, Chaoyang University of Technology, Taichung, Taiwan, Republic of China.
Drug Des Devel Ther. 2021 Aug 27;15:3711-3715. doi: 10.2147/DDDT.S328858. eCollection 2021.
Several osteoporosis drugs can continuously improve bone mass, but the impact on muscle mass is still unknown. This study aims to investigate how zoledronic acid monotherapy affected muscle mass in osteoporosis patients.
Patients from an osteoporosis database were divided into two groups in this retrospective cohort, case-control study: zoledronic acid-treated patients (n = 113) and a control group without osteoporosis treatment (n = 118). At four years, appendicular skeletal muscle mass (ASM) and appendicular skeletal muscle mass index (ASMI) were calculated using dual-energy X-ray absorptiometry. The differences in muscle mass between the groups were compared.
At baseline, there was no difference in sex, ASM, ASMI, and bone mineral density between the zoledronic acid treatment group and the control group. The treatment group's skeletal muscle mass increased by 841 g in ASM and 0.35 kg/m in ASMI after three years, while decreased in the control group.
This study for the first time demonstrated that that zoledronic acid is beneficial not only to the bone but also to muscle.
一些骨质疏松症药物可以持续改善骨量，但对肌肉量的影响仍不清楚。本研究旨在探讨唑来膦酸单药治疗对骨质疏松症患者肌肉量的影响。
本回顾性队列病例对照研究将骨质疏松症数据库中的患者分为两组：唑来膦酸治疗组（n=113）和未接受骨质疏松症治疗的对照组（n=118）。在四年时，使用双能 X 射线吸收法计算四肢骨骼肌量（ASM）和四肢骨骼肌量指数（ASMI）。比较两组间肌肉量的差异。
在基线时，唑来膦酸治疗组和对照组在性别、ASM、ASMI 和骨密度方面无差异。治疗组在三年内 ASM 增加了 841 克，ASMI 增加了 0.35 千克/平方米，而对照组则减少了。
本研究首次表明，唑来膦酸不仅对骨骼有益，而且对肌肉也有益。
